Bradley J Catalone
Overview
Explore the profile of Bradley J Catalone including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
154
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Molloy-Simard V, Lemyre J, Martel K, Catalone B
Am J Infect Control
. 2018 Nov;
47(3):243-250.
PMID: 30442443
Background: The health care community is increasingly aware of the processing challenges and infection risks associated with duodenoscopes owing to published reports of outbreaks and regulatory recalls. Studies have demonstrated...
2.
Passic S, Ferguson M, Catalone B, Kish-Catalone T, Kholodovych V, Zhu W, et al.
Biomed Pharmacother
. 2010 Nov;
64(10):723-32.
PMID: 21106331
Previous investigations showing that polydisperse biguanide (PDBG) molecules have activity against human immunodeficiency virus type 1 (HIV-1) also suggested a relationship between PDBG biologic activity and the lengths of hydrocarbon...
3.
Beer B, Doncel G, Krebs F, Shattock R, Fletcher P, Buckheit Jr R, et al.
Antimicrob Agents Chemother
. 2006 Jan;
50(2):713-23.
PMID: 16436731
The first product to be clinically evaluated as a microbicide contained the nonionic surfactant nonoxynol-9 (nonylphenoxypolyethoxyethanol; N-9). Many laboratories have used N-9 as a control compound for microbicide assays. However,...
4.
Catalone B, Miller S, Ferguson M, Malamud D, Kish-Catalone T, Thakkar N, et al.
Biomed Pharmacother
. 2005 Sep;
59(8):430-7.
PMID: 16154721
C31G, which has potent activity against the human immunodeficiency virus type 1 (HIV-1) and an established record of safety in animal studies and human trials, is a microbicidal agent comprised...
5.
Catalone B, Ferguson M, Miller S, Malamud D, Kish-Catalone T, Thakkar N, et al.
Biomed Pharmacother
. 2005 Sep;
59(8):460-8.
PMID: 16154719
Comparative assays of in vitro cytotoxicity using nonoxynol-9 (N-9) and the candidate microbicides C31G and sodium dodecyl sulfate (SDS) demonstrated that these agents, which are, respectively, characterized as nonionic, amphoteric,...
6.
Catalone B, Kish-Catalone T, Neely E, Budgeon L, Ferguson M, Stiller C, et al.
Antimicrob Agents Chemother
. 2005 Mar;
49(4):1509-20.
PMID: 15793133
C31G is currently the focus of clinical trials designed to evaluate this agent as a microbicidal and spermicidal agent. In the following studies, the in vivo safety of C31G was...
7.
Catalone B, Kish-Catalone T, Budgeon L, Neely E, Ferguson M, Krebs F, et al.
Antimicrob Agents Chemother
. 2004 Apr;
48(5):1837-47.
PMID: 15105142
Clinical trials evaluating the efficacy of nonoxynol-9 (N-9) as a topical microbicide concluded that N-9 offers no in vivo protection against human immunodeficiency virus type 1 (HIV-1) infection, despite demonstrated...
8.
Kensinger R, Catalone B, Krebs F, Wigdahl B, Schengrund C
Antimicrob Agents Chemother
. 2004 Apr;
48(5):1614-23.
PMID: 15105112
Evidence indicates that galactosyl ceramide (GalCer) and its 3'-sulfated derivative, sulfatide (SGalCer), may act as alternate coreceptors for human immunodeficiency virus type 1 (HIV-1) in CD4(-) cells. Glycosphingolipids (GSLs) may...
9.
Krebs F, Miller S, Catalone B, Fichorova R, Anderson D, Malamud D, et al.
Antimicrob Agents Chemother
. 2002 Jun;
46(7):2292-8.
PMID: 12069993
In experiments to assess the in vitro impact of the candidate microbicides nonoxynol 9 (N-9), C31G, and sodium dodecyl sulfate (SDS) on human immune and epithelial cell viability, cell lines...